Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma

被引：29

作者：

Liang, Renba ^{[1
,2
,3
]}

Yang, Liu ^{[1
]}

Zhu, Xiaodong ^{[2
,3
,4
]}

机构：

[1] Guangdong Med Univ, Dept Oncol, Affiliated Hosp, 27 South Ren Min Rd, Zhanjiang 524200, Guangdong, Peoples R China

[2] Guangxi Med Univ, Dept Oncol, Wuming Hosp, Nanning, Guangxi, Peoples R China

[3] Guangxi Med Univ, Dept Radiat Oncol, Canc Hosp, 71 He Di Rd, Nanning 530021, Guangxi, Peoples R China

[4] Guangxi Med Univ, Key Lab Early Prevent & Treatment Reg High Incide, Minist Educ, Nanning, Guangxi, Peoples R China

来源：

CANCER CONTROL | 2021年 / 28卷

基金：

中国国家自然科学基金;

关键词：

epidermal growth factor receptor; nasopharyngeal carcinoma; nimotuzumab; INTENSITY-MODULATED RADIOTHERAPY; GROWTH-FACTOR RECEPTOR; CONCURRENT CHEMOTHERAPY; CISPLATIN; EXPERIENCE; 5-FLUOROURACIL; MULTICENTER; COMBINATION; EFFICACY;

D O I：

10.1177/1073274821989301

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epidermal growth factor receptor (EGFR) is highly expressed in most of Nasopharyngeal carcinoma (NPC) samples and is associated with poor outcomes. Therefore, targeting EGFR may be a promising strategy to improve patient prognosis. Nimotuzumab is a humanized anti-EGFR monoclonal antibody. Recently, accumulating evidence has demonstrated that combination nimotuzumab and induction chemotherapy, radiotherapy, or concurrent chemoradiotherapy confer benefits for patients with NPC. Moreover, the side effects of such regimes are tolerable. In this review, we focus on the current data of nimotuzumab in clinical trials in the treatment of NPC.

引用

页数：6

共 28 条

[1] ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics [J].

Arteaga, Carlos L. ;

Engelman, Jeffrey A. .

CANCER CELL, 2014, 25 (03) :282-303

[2]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[3] Nasopharyngeal carcinoma [J].

Chen, Yu-Pei ;

Chan, Anthony T. C. ;

Quynh-Thu Le ;

Blanchard, Pierre ;

Sun, Ying ;

Ma, Jun .

LANCET, 2019, 394 (10192) :64-80

[4] NCCN Guidelines® Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines [J].

Colevas, A. Dimitrios ;

Yom, Sue S. ;

Pfister, David G. ;

Spencer, Sharon ;

Adelstein, David ;

Adkins, Douglas ;

Brizel, David M. ;

Burtness, Barbara ;

Busse, Paul M. ;

Caudell, Jimmy J. ;

Cmelak, Anthony J. ;

Eisele, David W. ;

Fenton, Moon ;

Foote, Robert L. ;

Gilbert, Jill ;

Gillison, Maura L. ;

Haddad, Robert I. ;

Hicks, Wesley L., Jr. ;

Hitchcock, Ying J. ;

Jimeno, Antonio ;

Leizman, Debra ;

Maghami, Ellie ;

Mell, Loren K. ;

Mittal, Bharat B. ;

Pinto, Harlan A. ;

Ridge, John A. ;

Rocco, James ;

Rodriguez, Cristina P. ;

Shah, Jatin P. ;

Weber, Randal S. ;

Witek, Matthew ;

Worden, Frank ;

Zhen, Weining ;

Burns, Jennifer L. ;

Darlow, Susan D. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05) :479-490

[5] Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial [J].

Huang, Jian-feng ;

Zhang, Fu-zheng ;

Zou, Qin-zhou ;

Zhou, Le-yuan ;

Yang, Bo ;

Chu, Jian-jun ;

Yu, Jia-hua ;

Zhang, Hao-wen ;

Yuan, Xiao-peng ;

Tai, Guo-mei ;

Liu, Fen-ju ;

Ma, C-M Charlie .

ONCOTARGET, 2017, 8 (02) :2457-2465

[6] Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma [J].

Huang, Jianfeng ;

Zou, Qinzhou ;

Qian, Danqi ;

Zhou, Leyuan ;

Yang, Bo ;

Chu, Jianjun ;

Pang, Qingfeng ;

Wang, Kewei ;

Zhang, Fuzheng .

ONCOTARGETS AND THERAPY, 2017, 10 :5835-5841

[7] Emerging biomarkers in head and neck cancer in the era of genomics [J].

Kang, Hyunseok ;

Kiess, Ana ;

Chung, Christine H. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (01) :11-26

[8] A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma [J].

Li, H. M. ;

Li, P. ;

Qian, Y. J. ;

Wu, X. ;

Xie, L. ;

Wang, F. ;

Zhang, H. ;

Liu, L. .

BMC CANCER, 2016, 16

[9] Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis [J].

Liu, Zhi-gang ;

Zhao, Yu ;

Tang, Jiao ;

Zhou, Yu-juan ;

Yang, Wen-juan ;

Qiu, Yan-fang ;

Wang, Hui .

ONCOTARGET, 2016, 7 (17) :24429-24435

[10] Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study [J].

Lu, Ying ;

Chen, Dagui ;

Liang, Jinhui ;

Gao, Jianquan ;

Luo, Zhanxiong ;

Wang, Rensheng ;

Liu, Wenqi ;

Huang, Changjie ;

Ning, Xuejian ;

Liu, Meilian ;

Huang, Haixin .

BMC CANCER, 2019, 19 (01)

← 1 2 3 →